Press coverage about Clovis Oncology (NASDAQ:CLVS) has been trending somewhat positive this week, according to Accern Sentiment Analysis. The research firm scores the sentiment of media coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Clovis Oncology earned a news sentiment score of 0.19 on Accern’s scale. Accern also gave media headlines about the biopharmaceutical company an impact score of 45.8519629571358 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
Several research firms have issued reports on CLVS. Zacks Investment Research downgraded shares of Clovis Oncology from a “hold” rating to a “sell” rating in a report on Tuesday, October 3rd. J P Morgan Chase & Co reaffirmed an “overweight” rating and set a $111.00 price objective (up from $72.00) on shares of Clovis Oncology in a report on Tuesday, June 20th. Bank of America Corporation decreased their price objective on shares of Clovis Oncology from $103.00 to $75.00 and set a “buy” rating on the stock in a report on Tuesday, June 20th. Leerink Swann decreased their price objective on shares of Clovis Oncology to $107.00 and set an “outperform” rating on the stock in a report on Friday, August 18th. Finally, Oppenheimer Holdings, Inc. reaffirmed a “hold” rating on shares of Clovis Oncology in a report on Monday, September 11th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating and twelve have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $87.09.
Shares of Clovis Oncology (NASDAQ:CLVS) opened at 83.50 on Tuesday. The firm’s market capitalization is $4.08 billion. Clovis Oncology has a 52-week low of $25.50 and a 52-week high of $99.45. The company’s 50-day moving average is $75.51 and its 200 day moving average is $70.59.
Clovis Oncology (NASDAQ:CLVS) last released its quarterly earnings data on Wednesday, August 2nd. The biopharmaceutical company reported ($1.29) EPS for the quarter, missing the consensus estimate of ($1.27) by ($0.02). The company had revenue of $14.62 million for the quarter, compared to analyst estimates of $13.07 million. During the same quarter in the previous year, the company earned ($2.07) EPS. The firm’s quarterly revenue was down 32.5% on a year-over-year basis. Equities analysts expect that Clovis Oncology will post ($7.55) earnings per share for the current fiscal year.
In related news, insider Gillian C. Ivers-Read sold 3,000 shares of the business’s stock in a transaction dated Friday, September 15th. The shares were sold at an average price of $69.50, for a total value of $208,500.00. Following the completion of the transaction, the insider now owns 191,583 shares of the company’s stock, valued at approximately $13,315,018.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director James C. Blair sold 18,450 shares of the business’s stock in a transaction dated Friday, August 4th. The shares were sold at an average price of $78.61, for a total transaction of $1,450,354.50. Following the completion of the transaction, the director now directly owns 2,185 shares of the company’s stock, valued at approximately $171,762.85. The disclosure for this sale can be found here. Insiders sold a total of 27,450 shares of company stock valued at $2,143,685 in the last three months. 12.50% of the stock is currently owned by corporate insiders.
ILLEGAL ACTIVITY NOTICE: This report was first posted by Transcript Daily and is the property of of Transcript Daily. If you are accessing this report on another publication, it was stolen and reposted in violation of U.S. & international copyright laws. The correct version of this report can be read at https://transcriptdaily.com/2017/10/10/clovis-oncology-clvs-earning-somewhat-positive-press-coverage-study-finds.html.
About Clovis Oncology
Clovis Oncology, Inc is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company’s product candidates include Rociletinib, Rubraca (Rucaparib) and Lucitanib. Rucaparib is an oral, small molecule poly adenosine diphosphate (ADP)-ribose polymerase (PARP) inhibitor of PARP1, PARP2 and PARP3 approved as a monotherapy for the treatment of patients with deleterious breast cancer (BRCA) (human genes associated with the repair of damaged deoxyribonucleic acid (DNA)) mutation (germline and/or somatic) associated advanced ovarian cancer.
Receive News & Ratings for Clovis Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology Inc. and related companies with MarketBeat.com's FREE daily email newsletter.